“CAR-T” (Chimeric Receptor-T Cell)
Sorrento’s cellular therapy programs focus on Chimeric Antigen Receptor-T Cell (CAR-T) for adoptive cellular immunotherapy to treat both solid and liquid tumors.
We believe our CD38 CAR-T has the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity. The company’s CD38 CAR-T candidate is being evaluated in multiple myeloma (MM). The program has successfully demonstrated strong preclinical anti-tumor activity in animal models and we plan to submit Investigational New Drug (IND) applications with the U.S. Food and Drug Administration for at least one of the CAR-T programs in 2017. We have also reported data from Phase I trials of our carcinoembryonic antigen (CEA) and prostate-specific membrane antigen (PSMA) directed CAR-T programs. Additionally, the company is assessing our CD123 CAR-T in acute myeloid leukemia (AML).